secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-06-11T23:59:59+00:00
Accession:  0001193125-24-158751
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma obtains composition of matter patent for obicetrapib extending IP to July 2043
--------------------------------------------------------------------------------

- USPTO issued patent 12,006,305 covering amorphous obicetrapib hemicalcium, the product form for potential commercialization.
- Patent protection extends to July 2043, over 9 years beyond prior second-generation patent expiration in 2034.
- Nine total patents now issued or allowed by USPTO covering obicetrapib and its uses.
- Patent eligible for listing in FDA Orange Book as drug substance patent if product approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524158751/0001193125-24-158751-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524158751/d851893d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-158751

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer